Table 3. Dose intensities (first 12 weeks; medians and IQRs).
|
Arms A+C (no cetuximab)
|
Arm B (cetuximab)
|
||||
|---|---|---|---|---|---|
| OxMdG | XELOX | OxMdG | XELOX | Total | |
| Total | 203 | 333 | 102 | 166 | 804 |
| Complete data on first round of treatment (0–12 weeks) | 158 | 247 | 76 | 119 | 600 |
| Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | |
|---|---|---|---|---|---|
| 5FU infusion | 91 (81, 99) | 85 (78, 94) | 88 (80, 97) | ||
| 5FU bolus | 91 (75, 99) | 83 (68, 93) | 88 (71, 97) | ||
| Capecitabine | 96 (86, 100) | 88 (80, 100) | 93 (84, 100) | ||
| Oxaliplatin | 89 (82, 98) | 97 (89, 100) | 86 (78, 94) | 92 (80, 99) | 93 (83, 99) |
| Cetuximab, day 1 | 85 (78, 94) | 96 (87, 100) | 92 (81, 99) | ||
| Cetuximab, day 8 | 83 (75, 92) | 93 (78, 100) | 89 (77, 99) | ||
| Cetuximab, day 15 | 91 (75, 100) | 91 (75, 100) |
5FU=5-fluorouracil.